208 related articles for article (PubMed ID: 30713808)
1. Pomalidomide increases immune surface marker expression and immune recognition of oncovirus-infected cells.
Davis DA; Shrestha P; Aisabor AI; Stream A; Galli V; Pise-Masison CA; Tagawa T; Ziegelbauer JM; Franchini G; Yarchoan R
Oncoimmunology; 2019; 8(2):e1546544. PubMed ID: 30713808
[TBL] [Abstract][Full Text] [Related]
2. Transient Viral Activation in Human T Cell Leukemia Virus Type 1-Infected Macaques Treated With Pomalidomide.
Gutowska A; McKinnon K; Sarkis S; Doster MN; Bissa M; Moles R; Stamos JD; Rahman MA; Washington-Parks R; Davis D; Yarchoan R; Franchini G; Pise-Masison CA
Front Med (Lausanne); 2022; 9():897264. PubMed ID: 35602479
[TBL] [Abstract][Full Text] [Related]
3. Restoration of immune surface molecules in Kaposi sarcoma-associated herpes virus infected cells by lenalidomide and pomalidomide.
Davis DA; Mishra S; Anagho HA; Aisabor AI; Shrestha P; Wang V; Takamatsu Y; Maeda K; Mitsuya H; Zeldis JB; Yarchoan R
Oncotarget; 2017 Aug; 8(31):50342-50358. PubMed ID: 28881567
[TBL] [Abstract][Full Text] [Related]
4. CDK4/6 inhibitors sensitize gammaherpesvirus-infected tumor cells to T-cell killing by enhancing expression of immune surface molecules.
Wu Y; Shrestha P; Heape NM; Yarchoan R
J Transl Med; 2022 May; 20(1):217. PubMed ID: 35562811
[TBL] [Abstract][Full Text] [Related]
5. Pomalidomide restores immune recognition of primary effusion lymphoma through upregulation of ICAM-1 and B7-2.
Shrestha P; Davis DA; Jaeger HK; Stream A; Aisabor AI; Yarchoan R
PLoS Pathog; 2021 Jan; 17(1):e1009091. PubMed ID: 33411730
[TBL] [Abstract][Full Text] [Related]
6. Mechanism and therapeutic implications of pomalidomide-induced immune surface marker upregulation in EBV-positive lymphomas.
Jaeger HK; Davis DA; Nair A; Shrestha P; Stream A; Yaparla A; Yarchoan R
Sci Rep; 2023 Jul; 13(1):11596. PubMed ID: 37463943
[TBL] [Abstract][Full Text] [Related]
7. Human T-cell leukemia virus type 1 (HTLV-1) p12I down-modulates ICAM-1 and -2 and reduces adherence of natural killer cells, thereby protecting HTLV-1-infected primary CD4+ T cells from autologous natural killer cell-mediated cytotoxicity despite the reduction of major histocompatibility complex class I molecules on infected cells.
Banerjee P; Feuer G; Barker E
J Virol; 2007 Sep; 81(18):9707-17. PubMed ID: 17609265
[TBL] [Abstract][Full Text] [Related]
8. The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules.
Keating S; Prince S; Jones M; Rowe M
J Virol; 2002 Aug; 76(16):8179-88. PubMed ID: 12134023
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus encoded interleukin-10 inhibits HLA-class I, ICAM-1, and B7 expression on human monocytes: implications for immune evasion by EBV.
Salek-Ardakani S; Arrand JR; Mackett M
Virology; 2002 Dec; 304(2):342-51. PubMed ID: 12504574
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of B7 molecules by the Epstein-Barr virus enhances susceptibility to lysis by a human NK-like cell line.
Montel AH; Morse PA; Brahmi Z
Cell Immunol; 1995 Jan; 160(1):104-14. PubMed ID: 7531116
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus-infected B cells of males with the X-linked lymphoproliferative syndrome stimulate and are susceptible to T-cell-mediated lysis.
Jäger M; Benninger-Döring G; Prang N; Sylla BS; Laumbacher B; Wank R; Wolf H; Schwarzmann F
Int J Cancer; 1998 May; 76(5):694-701. PubMed ID: 9610728
[TBL] [Abstract][Full Text] [Related]
12. Epstein-Barr virus permissively infects human syncytiotrophoblasts in vitro and induces replication of human T cell leukemia-lymphoma virus type I in dually infected cells.
Tóth FD; Aboagye-Mathiesen G; Nemes J; Liu X; Andirkó I; Hager H; Zdravkovic M; Szabó J; Kiss J; Aranyosi J; Ebbesen P
Virology; 1997 Mar; 229(2):400-14. PubMed ID: 9126252
[TBL] [Abstract][Full Text] [Related]
13. Downregulation of IL-10 secretion and enhanced antigen-presenting abilities following HTLV-I infection of T cells.
Scholz C; Hafler DA; Höllsberg P
J Neurosci Res; 1996 Sep; 45(6):786-94. PubMed ID: 8892090
[TBL] [Abstract][Full Text] [Related]
14. Induction of the Lytic Cycle Sensitizes Epstein-Barr Virus-Infected B Cells to NK Cell Killing That Is Counteracted by Virus-Mediated NK Cell Evasion Mechanisms in the Late Lytic Cycle.
Williams LR; Quinn LL; Rowe M; Zuo J
J Virol; 2016 Jan; 90(2):947-58. PubMed ID: 26537677
[TBL] [Abstract][Full Text] [Related]
15. HLA Class I Downregulation by HIV-1 Variants from Subtype C Transmission Pairs.
Ende Z; Deymier MJ; Claiborne DT; Prince JL; Mónaco DC; Kilembe W; Allen SA; Hunter E
J Virol; 2018 Apr; 92(7):. PubMed ID: 29321314
[TBL] [Abstract][Full Text] [Related]
16. Control of human herpes virus type 8-associated diseases by NK cells.
Sirianni MC; Campagna M; Scaramuzzi D; Carbonari M; Toschi E; Bacigalupo I; Monini P; Ensoli B
Ann N Y Acad Sci; 2007 Jan; 1096():37-43. PubMed ID: 17405914
[TBL] [Abstract][Full Text] [Related]
17. Correlation of major histocompatibility complex class I downregulation with resistance of human T-cell leukemia virus type 1-infected T cells to cytotoxic T-lymphocyte killing in a rat model.
Ohashi T; Hanabuchi S; Suzuki R; Kato H; Masuda T; Kannagi M
J Virol; 2002 Jul; 76(14):7010-9. PubMed ID: 12072501
[TBL] [Abstract][Full Text] [Related]
18. Lymphotropic viruses, Epstein-Barr virus (EBV) and human T-cell lymphotropic virus-I (HTLV-I)/adult T-cell leukemia virus (ATLV), and HTLV-III/human immune deficiency virus (HIV) as etiological agents of malignant lymphoma and immune deficiency.
Purtilo DT
AIDS Res; 1986 Dec; 2 Suppl 1():S1-6. PubMed ID: 2881552
[TBL] [Abstract][Full Text] [Related]
19. Syncytium-inhibiting monoclonal antibodies produced against human T-cell lymphotropic virus type 1-infected cells recognize class II major histocompatibility complex molecules and block by protein crowding.
Hildreth JE
J Virol; 1998 Dec; 72(12):9544-52. PubMed ID: 9811687
[TBL] [Abstract][Full Text] [Related]
20. The innate and T-cell mediated immune response during acute and chronic gammaherpesvirus infection.
Rex V; Zargari R; Stempel M; Halle S; Brinkmann MM
Front Cell Infect Microbiol; 2023; 13():1146381. PubMed ID: 37065193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
